pharma · Hypertension · Breast Neoplasms
Pfizer
NovaPharmaNews editorial coverage mentioning Pfizer — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- New York 10017, US
- Employees
- 103,316
- Programs
- 0
- Drugs
- 63
- Patents
- 0
News & analysis
NovaPharmaNews articles mentioning Pfizer — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning Pfizer — regulatory, clinical, and market analysis.
Eye drugs list: Sodium hyaluronate, tafluprost, tobramycin uses
This plan organizes a tightly sourced Eye drugs list around dry eyes, glaucoma, and eye infections. It keeps the focus on what the evidence confirms and avoids unsupported market or investment claims.
Danuglipron Phase 3 Watch After Pfizer’s Phase 2b Obesity Win
Pfizer said its oral GLP-1 danuglipron met the primary endpoint in a Phase 2b obesity trial, showing a statistically significant change in body weight from baseline. The result strengthens the case for Pfizer's oral GLP-1 strategy and sets up investor and BD scrutiny around Phase 3 design, safety, and differentiation.
Pfizer's Danuglipron Hits Phase 2b Obesity Endpoint
Pfizer said danuglipron, its oral GLP-1 receptor agonist, met the primary endpoint in a Phase 2b obesity trial with statistically significant weight loss versus baseline. The result strengthens the case for Danuglipron Phase 3 planning and gives BD and investor teams a fresh benchmark against other oral GLP-1 programs.
Pfizer berobenatide: VESPER-3 monthly GLP-1
Pfizer's monthly GLP-1 RA berobenatide (acquired from Metsera) shows continued weight loss in VESPER-3 Phase 2b data. This analysis covers efficacy, safety, and strategic implications for pharma teams.
Pfizer Berobenatide Phase 2b Monthly Dosing
Pfizer’s VESPER-3 Phase 2b showed up to 12.3% placebo-adjusted weight loss at week 28 with monthly berobenatide after weekly titration.
Rx Rundown: Pfizer, Hikma Pharmaceuticals, NewLimit — Drug Approvals & Catalyst Tracker
Pfizer, Hikma Pharmaceuticals, and NewLimit are at the center of recent FDA actions. This rundown covers approvals, withdrawals, and upcoming catalysts for pharma BD and investors.
BBSW AI Solution Event: Daily Roundup
Day 1 at BBSW AI Solution Summit 2026: AI moved from demos into discovery, trial operations, and regulatory workflows, while data quality and credibility evidence remained the binding constraints.